07:00 , Oct 26, 2015 |  BioCentury  |  Strategy

Collaborating on combos

As oncologists and drug developers converge on the idea that combination therapies built on a backbone of PD-L1 or PD-1 inhibitors could lead to cures for some cancers, or keep them at bay for years,...
07:00 , Jun 15, 2015 |  BC Week In Review  |  Company News

Areva Med, RadioMedix deal

Areva Med and RadioMedix partnered to co-develop a peptide receptor radio therapy to treat neuroendocrine tumors using somatostatin analogs combined with Areva Med’s lead-212 radionuclide. Areva Med will design and produce the peptide, and RadioMedix...
07:00 , Jun 3, 2013 |  BC Week In Review  |  Company News

Roche, Areva deal

Macrocyclics Inc., a subsidiary of Areva's Areva Med LLC (Bethesda, Md.) subsidiary, and Roche amended a 2012 deal under which the partners are creating an alpha radio-immunotherapy platform to treat cancer by assessing the efficacy...
07:00 , Jul 30, 2012 |  BC Week In Review  |  Company News

Roche, Areva deal

Areva's Areva Med LLC (Bethesda, Md.) subsidiary partnered with Roche to create an alpha radio-immunotherapy platform to treat cancer. Roche's Pharma Research & Early Development organization (pRED) will assess the efficacy of combining Roche-engineered antibodies...
00:48 , Jul 28, 2012 |  BC Extra  |  Company News

Areva Med, Roche to develop cancer radioimmunotherapy

Areva Med LLC (Bethesda, Md.) partnered with Roche (SIX:ROG; OTCQX:RHHBY) to develop an alpha radioimmunotherapy platform to treat cancer. Roche's Pharma Research & Early Development organization (pRED) will combine the pharma's antibodies with Areva's radionuclide,...
07:00 , May 14, 2012 |  BC Week In Review  |  Clinical News

212Pb-TCMC-Trastuzumab: Phase I started

Areva Med LLC , Bethesda, Md.   Product: 212Pb-TCMC-Trastuzumab   Business: Cancer   Molecular target: NA   Description: Trastuzumab combined with lead-212 isotope   Indication: Treat cancer that has metastasized the abdominal region   Endpoint:...